Ashling Wahner

Amandeep Salhotra, MD, discusses data that have demonstrated the anti-GVHD activity of post-transplant Orca-Q in patients with hematologic malignancies.

Sia Daneshmand, MD, discusses how TAR-200 addresses an unmet need for patients with BCG-unresponsive, high-risk NMIBC.

Cameron S. Bader, PhD, discusses findings from a study evaluating the prevalence of FOXP3 and Helios expression in Orca-T recipients.

The combination of nivolumab and ipilimumab is under priority review for the frontline treatment of patients with unresectable/metastatic MSI-H/dMMR CRC.

D. Ross Camidge, MD, PhD, discusses ways that ALK-positive NSCLC management has changed based on 5-year follow-up data with lorlatinib in the CROWN trial.

Claire Harrison, MD, FRCP, FRCPath, discusses research that may evolve the clinical use of JAK inhibitors and mutation-specific therapies in myelofibrosis.

The NCCN Guidelines for metastatic uveal melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease.

The combination of first-line avelumab and axitinib was effective and safe in a real-world analysis of patients with advanced RCC.

UGN-102 generated robust, durable responses in patients with low-grade, intermediate-risk NMIBC, in analyses of the phase 3 ENVISION and ATLAS studies.

The FDA has approved vimseltinib for the treatment of patients with tenosynovial giant cell tumor.

NKTR-255 combined with CD19-directed CAR T-cell therapy improved 6-month CR rates vs placebo in patients with relapsed/refractory large B-cell lymphoma.

Kathleen N. Moore, MD, MS, discusses ongoing trials of novel ADCs in ovarian cancer and the potential relevance of biomarker expression for these agents.

Neoadjuvant atezolizumab plus trastuzumab, pertuzumab, and abbreviated epirubicin generated pCRs in patients with early HER2-positive breast cancer.

Lisocabtagene maraleucel elicited a statistically significant overall response rate in adult patients with relapsed/refractory MZL.

KN026 plus docetaxel elicited durable responses and a manageable safety profile in patients with recurrent/metastatic HER2-positive breast cancer.

The FDA granted RMAT designation to gemogenovatucel-T for maintenance treatment after frontline chemotherapy in advanced HRP ovarian cancer.

The European Commission has approved serplulimab in combination with carboplatin and etoposide for the frontline treatment of adult patients with ES-SCLC.

The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in January 2025.

Anetumab ravtansine plus bevacizumab failed to improve efficacy vs paclitaxel plus bevacizumab in platinum-resistant high-grade ovarian cancer.

CAR T-cell therapies are associated with a risk for second primary cancers, and mitigation strategies for these toxic effects are warranted and under examination.

Azenosertib (ZN-c3) monotherapy was active in heavily pretreated patients with cyclin E1–positive platinum-resistant ovarian cancer.

Toni Choueiri, MD, discusses the unique features of NKT2152, the agent’s safety profile in RCC, and future research directions across GU oncology.

The FDA approved T-DXd for unresectable/metastatic HR+, HER2-low/-ultralow breast cancer that progressed on endocrine therapy in the metastatic setting.

Detectable ctDNA after neoadjuvant chemotherapy was associated with the recommendation for TME in patients with T1-3, N0 low or mid rectal cancer.

The EMA has accepted for review an MAA seeking the approval of nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with CIS.

ctDNA positivity was associated with worse DFS overall but significantly better DFS with celecoxib vs placebo in stage III resected colon cancer.

Zoldonrasib was well tolerated and associated with manageable AEs and preliminary antitumor activity in patients with KRAS G12D–mutated PDAC.

Galinpepimut-S demonstrated early efficacy signals in patients with acute myeloid leukemia in second complete remission or later.

David Rimm, MD, PhD, discusses pathology limitations that have been exacerbated by the current lineup of breast cancer IHC tests.